 |
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
Jun 6, 2013
|
10.0 KB |
|
| |
CAMBRIDGE, Mass., June 6, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating and often fatal rare diseases, today announced that on June 3, 2013, Aegerion granted stock options to p...
|
|
Aegerion Pharmaceuticals Receives Positive European CHMP Opinion for LOJUXTA(TM) (lomitapide) to Treat Homozygous Familial Hypercholesterolemia (HoFH)
May 31, 2013
|
13.4 KB |
|
| |
CAMBRIDGE, Mass., May 31, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel, life-altering therapies for patients with debilitating, often fatal, rare diseases, announced today that the European Committee for Medicinal Products for Human Use...
|
|
Aegerion Pharmaceuticals Announces Webcast of Investor Presentations at Upcoming Conferences
May 24, 2013
|
9.9 KB |
|
| |
CAMBRIDGE, Mass., May 24, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc.(Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare diseases, announced today that the company will participate in the Deutsche Bank 38th Annual Health Ca...
|
|
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
May 3, 2013
|
10.0 KB |
|
| |
CAMBRIDGE, Mass., May 3, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating and often fatal rare diseases, today announced that on May 1, 2013, Aegerion granted stock options to pur...
|
|
Aegerion Pharmaceuticals Announces Presentation at the Bank of America Merrill Lynch 2013 Healthcare Conference
May 3, 2013
|
9.7 KB |
|
| |
CAMBRIDGE, Mass., May 3, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc.(Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare diseases, announced today that the company will participate in the Bank of America Merrill Lynch 2013 H...
|
|
Aegerion Pharmaceuticals Announces First-Quarter 2013 Financial Results
Apr 30, 2013
|
19.9 KB |
|
| |
CAMBRIDGE, Mass., April 30, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating, often fatal, rare diseases, announced its financial results and business highlights for the first-qua...
|
|
Anne VanLent Appointed to Aegerion Pharmaceuticals' Board of Directors
Apr 29, 2013
|
10.4 KB |
|
| |
CAMBRIDGE, Mass., April 29, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating, often fatal, rare diseases, today announced the appointment of Anne M. VanLent to its Board of Direct...
|
|
Aegerion Pharmaceuticals Announces Presentation at the Needham Healthcare Conference
Apr 25, 2013
|
9.8 KB |
|
| |
CAMBRIDGE, Mass., April 25, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc.(Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare diseases, announced today that the company will participate in the 12th Annual Needham Healthcare Co...
|
|
Aegerion Pharmaceuticals to Announce First Quarter 2013 Financial Results on Tuesday, April 30
Apr 16, 2013
|
9.9 KB |
|
| |
CAMBRIDGE, Mass., April 16, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating, often fatal rare diseases, announced that the Company will host a conference call and live audio webc...
|
|
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
Apr 3, 2013
|
9.9 KB |
|
| |
CAMBRIDGE, Mass., April 3, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating and often fatal rare diseases, today announced that on April 1, 2013, Aegerion granted stock options to...
|
|
Aegerion Pharmaceuticals Announces Fourth-Quarter and Year-End 2012 Financial Results
Mar 6, 2013
|
76.3 KB |
|
| |
CAMBRIDGE, Mass., March 6, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating, often fatal rare diseases, announced its financial results and business highlights for the fourth-quar...
|
|
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
Mar 5, 2013
|
10.4 KB |
|
| |
CAMBRIDGE, Mass., March 5, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating and often fatal rare diseases, today announced that on March 1, 2013, Aegerion granted stock options to...
|
|
Aegerion Pharmaceuticals Observes Rare Disease Day
Feb 28, 2013
|
10.7 KB |
|
| |
CAMBRIDGE, Mass., Feb. 28, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc.(Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare diseases, announced today its alliance with the National Organization for Rare Disorders (NORD), Rare...
|
|
Aegerion Pharmaceuticals Announces Presentation at the Cowen and Company 33rd Annual Health Care Conference
Feb 27, 2013
|
10.1 KB |
|
| |
CAMBRIDGE, Mass., Feb. 27, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc.(Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare diseases, announced today that the company will participate in the Cowen and Company 33rd Annual Heal...
|
|
Aegerion Pharmaceuticals to Announce Fourth Quarter 2012 Financial Results on Wednesday, March 6
Feb 20, 2013
|
10.4 KB |
|
| |
CAMBRIDGE, Mass., Feb. 20, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating, often fatal rare diseases, announced that the Company will host a conference call and live audio webca...
|
|
Aegerion Pharmaceuticals Announces Webcast of Investor Presentations at Upcoming Conferences
Feb 7, 2013
|
10.3 KB |
|
| |
CAMBRIDGE, Mass., Feb. 7, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc.(Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare diseases, announced today that the company will participate in the 15th Annual BIO CEO & Investor Conf...
|
|
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
Feb 7, 2013
|
10.4 KB |
|
| |
CAMBRIDGE, Mass., Feb. 7, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating and often fatal rare diseases, today announced that on February 1, 2013, Aegerion granted stock options ...
|
|
Aegerion Pharmaceuticals Prices Public Offering of Common Stock
Jan 11, 2013
|
13.5 KB |
|
| |
CAMBRIDGE, Mass., Jan. 11, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) ("Aegerion"), a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating and often fatal rare diseases, today announced the pricing of an underwritten public offer...
|
|
Aegerion Pharmaceuticals Announces Proposed Public Offering of Common Stock
Jan 10, 2013
|
11.8 KB |
|
| |
CAMBRIDGE, Mass., Jan. 10, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) ("Aegerion"), a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating and often fatal rare diseases, today announced that it intends to offer for sale its commo...
|
|
Aegerion Pharmaceuticals Announces Key Business and Financial Objectives for 2013 as the Company Prepares for U.S. Launch of JUXTAPID(TM) (lomitapide) Capsules
Jan 7, 2013
|
67.3 KB |
|
| |
CAMBRIDGE, Mass., Jan. 7, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating, often fatal, rare diseases, today announced its business objectives for 2013 in conjunction with the 31...
|
|
|
Shareholder Briefcase
Printed Materials
Email Alerts
Download Library
Snapshot
RSS News Feeds
Delicious
Digg
Facebook
LinkedIn
Twitter
